Procalcitonin to reduce antimicrobial overuse in patients with lower respiratory tract infection: time for re-evaluation of our prescription culture?

Lancet Infect Dis. 2023 Apr;23(4):390-391. doi: 10.1016/S1473-3099(22)00757-5. Epub 2022 Dec 13.

Authors

Pradeesh Sivapalan¹, Jens-Ulrik Stæhr Jensen²

Affiliations

¹ Section of Respiratory Medicine, Department of Medicine, Herlev-Gentofte Hospital, Herlev, Denmark.
² Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen DK-2100, Denmark. Electronic address: jens.ulrik.jensen@regionh.dk.

PMID: 36525986
DOI: 10.1016/S1473-3099(22)00757-5

No abstract available

Publication types

Comment

MeSH terms

Anti-Bacterial Agents / therapeutic use
Anti-Infective Agents*
Biomarkers
Humans
Procalcitonin
Respiratory Tract Infections* / drug therapy

Substances

Procalcitonin
Anti-Infective Agents
Anti-Bacterial Agents
Biomarkers